Clinical course of critically ill non-COVID 19 ARDS patients using Itolizumab versus conventional treatment: A case series

Abstract

We tracked the inflammatory mediators and blood gases ratios to evaluate the progress of treatment with Itolizumab administered in 5 critically ill patients against other therapeutic options in COVID 19 negative patients admitted to the ICU with ARDS. All patients had PaO2/FiO2 ratio <200>25mm Hg, while inflammatory markers such as D-Dimer value of > 0.21 g/L and IL-6 values >150 up to 1250 pg/ml at the time of admission. Radiological images were evaluated for improvement, patients requiring ventilator support were intubated and when the patient’s PaO2 was within normal range, they were extubated. The prognostic indicators were measured till clinical outcomes in patients were met in all 10 patients of which 5 received Itolizumab on day 2 of hospitalization. All prognostic indicators showed a decline in inflammatory markers, proportionate improvement in PaO2/FiO2 values, and a reduction in PaCo2 values. All patients treated with Itolizumab were recovered and discharged, while one patient died and did not receive Itolizumab.